Literature DB >> 12183097

Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation.

Youn Seon Choi1, J Andrew Billings.   

Abstract

Opioid antagonists have well-established indications in the reversal of life-threatening opioid toxicity, but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-related constipation. We briefly review current understanding of opioid receptors, focusing on their complex role in gastrointestinal physiology. We summarize the pharmacology, conventional indications, and clinical usage of three major groups of opioid antagonists, including a promising new peripherally acting agent, methylnaltrexone, which is not commercially available. We suggest an approach to administering opioid antagonists for reduction of life-threatening opioid toxicity in patients with pain. The literature on opioid-induced constipation and its treatment with opioid-antagonists is reviewed in detail. Finally, other potential uses of opioid antagonists in palliative care are described, especially strategies for reducing such opioid side effects as nausea and pruritus and for improving analgesia or reducing tolerance by concomitantly administrating both an opioid agonist and low dosages of an antagonist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183097     DOI: 10.1016/s0885-3924(02)00424-4

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  32 in total

Review 1.  Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

2.  Standardized treatment of Chinese medicine decoction for cancer pain patients with opioid-induced constipation: a multi-center prospective randomized controlled study.

Authors:  Chang-ming Chen; Li-zhu Lin; En-xin Zhang
Journal:  Chin J Integr Med       Date:  2014-06-28       Impact factor: 1.978

Review 3.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

Review 4.  Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies.

Authors:  Ankush Sharma; M Mazen Jamal
Journal:  Curr Gastroenterol Rep       Date:  2013-07

Review 5.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 6.  Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.

Authors:  Amy P Abernethy; Jane L Wheeler; S Yousuf Zafar
Journal:  Curr Opin Support Palliat Care       Date:  2010-03       Impact factor: 2.302

7.  Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.

Authors:  Peter Deibert; Carola Xander; Hubert E Blum; Gerhild Becker
Journal:  Core Evid       Date:  2010-06-15

8.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

9.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

10.  Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness.

Authors:  Jennifer W Mack; Matthew Nilsson; Tracy Balboni; Robert J Friedlander; Susan D Block; Elizabeth Trice; Holly G Prigerson
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.